Combination Therapy With Tocilizumab and Dexamethasone Cost-Effectively Reduces Coronavirus Disease 2019 Mortality. (6th May 2021)
- Record Type:
- Journal Article
- Title:
- Combination Therapy With Tocilizumab and Dexamethasone Cost-Effectively Reduces Coronavirus Disease 2019 Mortality. (6th May 2021)
- Main Title:
- Combination Therapy With Tocilizumab and Dexamethasone Cost-Effectively Reduces Coronavirus Disease 2019 Mortality
- Authors:
- Sinha, Pranay
Linas, Benjamin P - Abstract:
- Abstract: Recent randomized trials suggest that interleukin-6 inhibitors reduce mortality due to severe coronavirus disease 2019. Using a decision tree model, we found that tocilizumab is cost-effective with an estimated incremental cost-effectiveness ratio of $16 520 per quality-adjusted life year gained (95% credible interval, 10 760–51 530).
- Is Part Of:
- Clinical infectious diseases. Volume 73:Number 11(2021)
- Journal:
- Clinical infectious diseases
- Issue:
- Volume 73:Number 11(2021)
- Issue Display:
- Volume 73, Issue 11 (2021)
- Year:
- 2021
- Volume:
- 73
- Issue:
- 11
- Issue Sort Value:
- 2021-0073-0011-0000
- Page Start:
- 2116
- Page End:
- 2118
- Publication Date:
- 2021-05-06
- Subjects:
- tocilizumab -- COVID-19 -- IL-6 inhibitors -- cost-effectiveness -- health economics
Communicable diseases -- Periodicals
616.905 - Journal URLs:
- http://cid.oxfordjournals.org ↗
http://ukcatalogue.oup.com/ ↗
http://www.journals.uchicago.edu/CID/journal ↗
http://www.jstor.org/journals/10584838.html ↗ - DOI:
- 10.1093/cid/ciab409 ↗
- Languages:
- English
- ISSNs:
- 1058-4838
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3286.293860
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 20236.xml